Pharmaceutical company PJSC “Pharmak” (Kyiv) expects growth to 2018 of pharmacy sales of their products by 18% in the national currency, said the Director of marketing at the company Susanna Khalilov on a press-conferences in Agency “Interfax-Ukraine” on Thursday.

“Next year is more optimistic than 10% in the national currency. We see 17-18%. As to how it will happen in real terms, no one can predict. If you get 4%, we assume that this is a positive moment,” she said.

S. Khalilov also noted that in connection with changes in the health system, the company expects in the next year changes in sales of certain groups of drugs.

“Healthcare reform affects this segment (prescription drugs – if). 2018 for the entire market, including for us, the end of the formation processes of changes in the healthcare industry,” she said .

According to the company “Business Credit”, in the first 11 months of 2017 “Farmak” is one of three leaders by volume of pharmacy sales in money and volume terms.

As reported on the forecast of the “Business Credit”, the growth of pharmacy sales of domestic drugs in 2018 may reach 4% in packaging and 10% in the national currency.

Farmak, the largest pharmaceuticals company in Ukraine. Produces up to 200 kinds of medicines.

The ultimate beneficiary of the company is Chairman of the Supervisory Board Phil Zhebrovskaya.

Farmak is a member of the Association “Manufacturers of drugs of Ukraine” (APLU).